Kenvue Stock Recovers After Trump's Unsubstantiated Tylenol-Autism Claims
ReutersOctober 5, 20251 min5,982 views
11 connections·12 entities in this video→Kenvue Stock Rebounds
- 📈 Kenvue's shares saw a significant rebound, rising as much as 7% after hitting a record low.
- 💡 This recovery occurred as investors largely dismissed unproven claims made by former President Donald Trump.
Trump's Tylenol Claims
- 🗣️ Donald Trump linked autism to the use of Tylenol (acetaminophen/paracetamol) by pregnant women.
- ⚠️ Analysts and doctors have noted that Trump presented no new scientific evidence to support these claims.
Scientific and Regulatory Stance
- 🔬 Kenvue, spun off from Johnson & Johnson, reiterated that there is no scientific link between Tylenol and autism.
- 🇪🇺 Health agencies in the EU and UK confirmed the safety of paracetamol during pregnancy.
- 🇺🇸 The US FDA stated it would update labels to reflect a possible link to neurological conditions but emphasized that no causal relationship has been established.
Market Impact
- 📉 Prior to Trump's remarks, Kenvue's shares had fallen approximately 7.5% to an all-time low.
- 💰 Tylenol is a significant product for Kenvue, generating roughly $1 billion in annual sales.
Knowledge graph12 entities · 11 connections
How they connect
An interactive map of every person, idea, and reference from this conversation. Hover to trace connections, click to explore.
Hover · drag to explore
12 entities
Chapters1 moments
Key Moments
Transcript6 segments
Full Transcript
Topics11 themes
What’s Discussed
KenvueTylenolAutismPregnancyDonald TrumpAcetaminophenParacetamolStock MarketScientific EvidenceFDAJohnson & Johnson
Smart Objects12 · 11 links
Companies· 4
Products· 2
Concepts· 3
Event· 1
Locations· 2